Spots Global Cancer Trial Database for PROton Versus Photon Therapy for Esophageal Cancer - a Trimodality Strategy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: PROton Versus Photon Therapy for Esophageal Cancer - a Trimodality Strategy
Official Title: PROton Versus Photon Therapy for Esophageal Cancer - a Trimodality Strategy (PROTECT) A Multicenter International Randomized Phase III Study of Neoadjuvant Proton Versus Photon Chemoradiotherapy in Locally Advanced Esophageal Cancer
Study ID: NCT05055648
Study Description
Brief Summary: The PROTECT trial will test the hypothesis that proton (PT) -enabled radiation dose reductions to sensitive, normal tissues will result in lower rates of treatment-related pulmonary complications in esophageal cancer compared to standard photon therapy (XT).
Detailed Description: PROTECT is a unblinded international multicenter randomized phase III study for patients with operable EC or EGC receiving nCXT (standard of care) or nCPT (intervention). The study will be open-label for the patient and the treating physician. The radiation dose is either 41.4 Gy in 23 fractions, five fractions per week or 50.4 Gy in 28 fractions, five fractions per week. Prior to trial opening, each proton center will determine a single dose regimen for all patients treated in that specific proton center and its assigned photon centers. The protocol prescribes that all referring centers will use the same chemotherapy regimen, which is weekly carboplatin (AUC 2), and paclitaxel (50 mg/m2), five cycles, irrespective of choice of dose regimen. Chemotherapy is a non-investigational drug. Prior to referral to any proton therapy center, patients will be randomed (1:1) to either nCXT or nCPT. Only patients randomized to the PT arm will be referred to a PT center. Randomization will be performed centrally using an online 24-hour web-based system maintained by the Clinical Trial Office at Aarhus University Hospital, ensuring allocation concealment to the clinical investigators. The method of randomization will be stratified permuted blocks of size 4 and 6 (selected randomly) with the following strata: * Histopathology (non-squamous vs squamous cell carcinoma) * Planned surgical technique (open versus minimal invasive/robotic or hybrid) * Proton center and sites assigned to this center (which will deliver the nCXT)
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Catholic University of Leuven, Leuven, , Belgium
Aarhus University Hospital (AUH), Aarhus, , Denmark
Centre Léon Bérard (CLB), Lyon, , France
Centre Antoine Lacassagne (CAL), Nice, , France
Institut Curie, Paris, , France
Technische Universität Dresden (TUD), Dresden, , Germany
Centro Nazionale di Adroterapia Oncologica (CNAO), Pavia, , Italy
Azienda Provinciale Per I Servizi Sanitari (APSS), Trento, , Italy
Academisch Ziekenhuis Groningen (UMCG), Groningen, , Netherlands
Stichting Maastricht Radiation Oncology (MAASTRO), Maastricht, , Netherlands
Paul Scherrer Institute (PSI), Villigen, , Switzerland
University College London Hospital (UCLH), London, , United Kingdom
The Christie NHS foundation trust, Manchester, , United Kingdom
Contact Details
Name: Marianne Nordsmark, Dr.
Affiliation: University of Aarhus
Role: STUDY_DIRECTOR
Name: Karin Haustermans, Dr.
Affiliation: UKleuven
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
